Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 12:23 PM
September 2025
In this educational session, Stacie Egan, DNP at Ogden Clinic GI in Ogden, Utah, shares practical insights on managing patients with MASH and fibrosis in clinical practice. Drawing from her experience treating patients with F2–F3 fibrosis, Stacy highlights the effectiveness of emerging pharmacotherapies and the positive outcomes she has seen in her patients. She emphasizes the critical role of primary care providers as gatekeepers in identifying at-risk patients, particularly those with metabolic syndrome, type 2 diabetes, obesity, hypertension, or hyperlipidemia. By utilizing simple tools like the FIB-4 score, primary care teams can begin the process of risk stratification and ensure that patients receive timely referrals for additional testing such as FibroScan, MRE, or liver biopsy. Stacie also discusses the importance of distinguishing between low, indeterminate, and high-risk patients, ensuring that those with advanced fibrosis (F2, F3, and F4) receive appropriate treatment, monitoring, and, when needed, referral to hepatology for transplant evaluation. This video serves as an important resource for providers across specialties, reinforcing the need for collaboration to detect and treat MASH with fibrosis early, improve patient outcomes, and help reverse steatosis and fibrosis.
Related Podcast
MASLD Pharmacotherapy With Whitney Steinmetz
August 2025
Join Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, for an in-depth review of pharmacotherapy in MASLD and MASH, presented as part of the GHAPP MASLD Community Network. In this comprehensive CME-eligible session, Whitney explores the multimodal treatment approach for patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), focusing on three therapeutic pillars: obesity management, cardiometabolic risk reduction, and liver-directed therapies. The discussion covers mechanisms, clinical trial data, and practical considerations for key treatment options, including GLP-1 receptor agonists, vitamin E, pioglitazone, and resmetirom (Rezdiffra). Whitney highlights findings from landmark studies such as ESSENCE, PIVENS, and MAESTRO-NASH, and explains how thyroid hormone receptor beta activation through resmetirom reduces hepatic fat, inflammation, and fibrosis in F2-F3 patients. She also offers guidance on non-invasive monitoring (FibroScan, MRE, ALT), drug–drug interactions, and how evolving guidelines from AASLD and ESLD shape clinical decision-making. Whether you're treating early-stage fatty liver disease or managing moderate fibrosis in primary care or hepatology, this video provides evidence-based insights to optimize long-term outcomes through targeted pharmacologic strategies and patient-centered care.
Watch Now
APP Insight: Common Questions from Patients About MASH
June 2025
In this insightful video, Patrick Horne, NP, from the University of Florida, addresses some of the most frequently asked questions from patients diagnosed with MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction–Associated Steatohepatitis). Drawing from his clinical experience, he answers common concerns such as: “How did I get fatty liver if I don’t drink alcohol?”, clarifying that alcohol is not a necessary factor in developing these conditions—rather, metabolic risk factors like obesity, diabetes, hypertension, and genetic predisposition play a significant role. Patrick also dives into lifestyle recommendations, including the importance of adopting a mediterranean diet, engaging in regular physical activity, and setting realistic weight loss goals. Additionally, he tackles the nuanced question of alcohol consumption in patients with MASLD/MASH, emphasizing individualized care depending on the stage of liver disease. This session is a must-watch for both patients and providers seeking practical, evidence-based guidance on managing metabolic liver disease.
Watch Now
Non-Invasive Testing With Jeremy Davis
September 2025
Join Jeremy Davis, NP, for a clear, clinic-ready walkthrough of non-invasive testing for MASLD/MASH. Using a real case, Jeremy shows how to risk-stratify patients starting with FIB-4 and when intermediate scores should trigger liver stiffness measurement. Learn practical cutoffs, image-quality checkpoints (valid measures, IQR/median), and common confounders (ALT/AST flares, cholestasis, recent meals, alcohol, obesity, ascites) that can overestimate stiffness. He contrasts pros/cons of VCTE vs. MRE, explains how to pair ELF with FibroScan, and maps decisions to AGA/AASLD-aligned pathways—who to refer, who to monitor, and how often to re-stage. The session closes with actionable counseling on lifestyle, weight loss targets, and cardiometabolic risk control to slow fibrosis progression while minimizing unnecessary biopsies.
Watch Now
Common Questions from Primary Care Providers About MASH
July 2025
In this educational video, Robin Soto, RN, MSN, FNP-BC from UC San Diego Health, answers common questions from primary care providers about the progression and management of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic-associated steatohepatitis). She addresses the often-misunderstood reality that fatty liver disease can progress to cirrhosis, even in patients with no history of alcohol use—challenging the stigma that surrounds liver disease. Robin explains how MASH is a progressive condition, and if left unmanaged, can lead to advanced fibrosis and liver failure. She also shares practical dietary advice for patients, highlighting the benefits of the Mediterranean diet—rich in healthy fats, fiber, and low in processed foods and sugars—as recommended by hepatology societies like AASLD. Importantly, she emphasizes that even modest weight loss (3–10%) can significantly improve steatosis, inflammation, and even reverse fibrosis. This video is a valuable resource for clinicians and patients alike, focused on prevention, early intervention, and empowering lifestyle changes.
Watch Now
Common Questions From Primary Care Providers About MASH
August 2025
In this overview on the MASLD Community Network, Oyin Penny, FNP with Premier Gastroenterology, addresses some of the most frequent questions primary care providers have when caring for patients with metabolic dysfunction–associated steatohepatitis (MASH). Learn when to screen patients for MASH, the key risk factors that should prompt evaluation, and when referral to gastroenterology or hepatology specialists is most appropriate. Oyin also explains how to monitor disease progression using non-invasive tests (NITs) such as FibroScan, MR elastography, and ELF tests. Whether you are a PCP managing patients with obesity, diabetes, hypertension, or abnormal liver imaging, this video provides essential guidance to help you identify high-risk patients earlier and optimize their care. Stay tuned for more expert insights and practical education from the MASH Community Network.
Watch Now
APP Insight: Misconceptions About Liver Health
June 2025
In this video, Anthony Derencius, PA-C at Pinnacle Clinical Research, clears up some of the most common misconceptions about liver health—offering valuable insights for both patients and healthcare providers. With extensive experience in hepatology, Anthony emphasizes that liver disease is often silent and asymptomatic, meaning many individuals may feel completely fine while living with a significant liver issue. He cautions against relying on a single lab result or imaging test to determine liver status, especially when assessing for conditions like cirrhosis, and stresses the importance of confirming findings through multiple diagnostic tools over time. Anthony also highlights the need for proactive screening, particularly in patients with risk factors such as obesity, diabetes, or a family history of liver disease. Early detection is key, and he encourages patients to advocate for their liver health by seeking evaluation—even if their provider hasn’t suggested it. This is a must-watch for anyone aiming to better understand the complexities of liver disease and the importance of early and accurate diagnosis.
Watch Now
MASLD vs MetALD With Jennifer Geremia
September 2025
In this GHAPP MASLD Community Network presentation, Jennifer Geremia, PA-C explains how to differentiate metabolic dysfunction–associated steatotic liver disease (MASLD) from metabolic dysfunction plus alcohol-associated liver disease (MetALD) and how to manage patients who sit on the MASLD–MetALD spectrum. Using a classic case (52-year-old with BMI 29.4, PCOS, hypertension, hyperlipidemia, ultrasound-confirmed steatosis, FibroScan 11.4 kPa [F3] and CAP 310), she shows how to combine history, “standard drink” counseling, AUDIT-C screening, and objective biomarkers like PEth to uncover under-reported alcohol use, quantify grams/day or week, and classify risk. You’ll learn practical algorithms for ruling out alternative etiologies, assessing cardiometabolic drivers, interpreting noninvasive tests, and estimating 5-year decompensation risk across MASLD, MetALD, and ALD. The session closes with actionable care steps: lifestyle and Mediterranean-style nutrition, exercise and weight-loss targets, strict alcohol cessation (and referral when appropriate), consideration of pharmacologic options in advanced fibrosis, and when to initiate HCC surveillance. Scan the QR code to confirm attendance and access more MASLD/MetALD education and resources.
Watch Now
MASLD Pharmacotherapy With Anthony Derencius
August 2025
Join Anthony Derencius, PA-C, sub-investigator at Pinnacle Clinical Research, for an in-depth, case-based discussion on the pharmacologic management of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Steatohepatitis) in this GHAPP MASLD Community Network presentation. With clinical insights from both hepatology practice and research, Anthony explores the multifactorial approach to managing metabolic liver disease—emphasizing weight loss strategies, GLP-1 receptor agonists, cardiovascular risk reduction, and liver-directed therapies. Learn how medications like semaglutide and tirzepatide play a role in weight loss and glycemic control, and how vitamin E and pioglitazone are still considered under specific circumstances. A major highlight includes the mechanism and clinical data behind resmetirom, the first FDA-approved therapy for MASH with F2–F3 fibrosis. Anthony explains its thyroid hormone receptor β-selectivity, efficacy data from the MAESTRO-NASH trial, real-world safety considerations, drug interactions, and monitoring protocols. This presentation is essential viewing for clinicians managing MASLD and MASH in both community and research settings, offering practical strategies, current guidelines, and a look into the future of liver-specific pharmacotherapy.
Watch Now
MASLD vs MetALD With Lindsay Pratt
October 2025
Learn from Lindsay Pratt, PA-C at the University of Colorado Hepatology Clinic, as she explores the evolving landscape of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-associated liver disease (MetALD) in this comprehensive, case-based discussion. Drawing on over 15 years of experience in hepatology and liver transplantation, Lindsay walks through real-world evaluation and management of a 52-year-old patient with hepatic steatosis, highlighting key diagnostic clues, lab interpretations, and the importance of incorporating objective biomarkers such as PEth testing to accurately assess alcohol use. This educational session provides clarity on differentiating MASLD, MASH, and MetALD, interpreting FibroScan results, and addressing cardiometabolic risk factors like obesity, hypertension, and hyperlipidemia. Pratt also emphasizes practical treatment strategies, including lifestyle modification, GLP-1 therapy, and alcohol cessation counseling, along with considerations for emerging therapies like resmetirom (Rezdiffra). APPs and hepatology clinicians will gain valuable insights into patient communication, disease classification, and evidence-based management approaches that can help slow progression, reduce fibrosis risk, and optimize liver outcomes.
Watch Now
NITs: A Practical Overview: Navigating the Basics
July 2025
Join Ellie Gonyeau, a nurse practitioner at Beth Israel in Boston, for an insightful podcast episode on metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH, and how to effectively use non-invasive testing (NITs) to evaluate and manage patients with fatty liver disease. Ellie breaks down the differences between MASLD and MASH—explaining why distinguishing simple steatosis from inflammatory liver injury matters for long-term outcomes. She covers first-line serum-based tools like FIB-4 and ELF score, as well as imaging-based modalities including FibroScan and MR elastography, helping clinicians understand when and how to apply each test. With practical tips on interpreting fibrosis risk thresholds, stratifying patients with metabolic comorbidities, and educating primary care teams, this episode emphasizes the power of early identification, appropriate triage, and collaborative care to prevent disease progression. Whether you're working in general GI, primary care, or hepatology, this episode equips you with tools to make liver disease detection more proactive and patient-centered.
Watch Now